Can You Get Allergy Shots for Pollen? Which Pollens Are Treatable

Allergy shots do not 'cure' pollen allergies in the permanent sense, but they can produce sustained remission in many patients — a clinically meaningful reduction in allergic reactivity that persists for years after completing the treatment course. Durham et al. (NEJM, 1999) demonstrated that grass pollen immunotherapy benefits persisted at least 3 years after stopping a completed 3-year course. The underlying allergic predisposition remains, but the immune system's reactivity to specific pollen triggers is durably reduced through the immunological changes — IgG4 blocking antibody induction, T-regulatory cell activation, IgE downregulation — that occur during treatment. Most patients completing a full 3-5 year pollen immunotherapy course experience significantly reduced symptoms, lower medication needs, and improved quality of life that continues well beyond the treatment endpoint.

Grass pollen allergies have the strongest and most consistent evidence of response to allergy shots, supported by multiple Cochrane reviews with large patient numbers across many countries. Ragweed pollen immunotherapy also has strong US trial evidence, with Nelson (JACI, 2007) showing 30-40% symptom reduction in meta-analysis. Birch tree pollen immunotherapy has strong European data and benefits from cross-reactivity with related tree species. Cedar and juniper pollen immunotherapy is supported by moderate evidence. In general, pollen allergies with well-standardized commercially available extracts — timothy grass, short ragweed, Bermuda grass, birch — have the most validated efficacy data. Non-standardized pollen extracts (some tree mixes, some weed species) have less consistent dosing and thus more variable outcomes. Your allergist will design your extract based on your specific documented sensitizations rather than pollen type alone.

Yes, allergy shots are effective for tree pollen allergies, though evidence strength varies by tree species. Birch pollen immunotherapy has the most extensive European evidence base and benefits from cross-reactivity across the birch family (Betulaceae) — treating birch can provide cross-protection against alder, hazel, and hornbeam, which share the major allergenic protein Bet v 1. Japanese cedar immunotherapy has been well-studied in Asian populations. Mountain cedar immunotherapy is commonly administered in the US South and Southwest. Oak, maple, and elm pollen immunotherapy is clinically practiced with moderate evidence. One practical consideration: many tree pollen extracts are not FDA-standardized (unlike grass and ragweed), which means potency and consistency vary more between manufacturers. Your allergist will select extracts from standardized manufacturers and calibrate dosing based on your skin test or IgE levels.

Yes — multi-pollen sensitization is the norm rather than the exception, and multi-allergen immunotherapy is standard US practice. Over 70% of pollen-allergic patients react to more than one pollen type, and most immunotherapy formulas include multiple pollen allergens in a single vial. Your allergist mixes extracts from your specific relevant pollen sensitizations into your personalized vial, adjusted for relative concentrations to ensure adequate dosing for each allergen. European guidelines have historically favored single-allergen protocols for purity of evidence, but US practice routinely uses multi-allergen mixes with good clinical outcomes. The main consideration in multi-allergen mixing is allergenicity compatibility — some extracts (particularly those containing proteases, such as mold) can degrade other extracts when mixed. Your allergist's formulation expertise ensures the right mixing strategy for your specific sensitization profile.

Yes — even if your allergies are only seasonal (spring pollen), allergy shot maintenance requires year-round injections. Immune tolerance does not self-maintain without regular antigen exposure. Monthly maintenance injections — continuing throughout the calendar year, not just during pollen season — are needed to sustain the IgG4 blocking antibodies and regulatory T-cell populations that suppress your allergic response. This surprises many patients: you develop seasonal symptoms but receive injections during the symptom-free months too. This is not inefficiency — it is mechanistically necessary. The AAAAI practice parameters require year-round maintenance injections for seasonal allergens. Some patients try to negotiate a seasonal-only maintenance schedule; research does not support this approach as producing equivalent tolerance compared to year-round injections. The good news is that maintenance phase requires only monthly visits, so the annual commitment is approximately 12 appointments.

Allergy shots and nasal corticosteroid sprays work by different mechanisms and serve different clinical roles. Nasal steroids (fluticasone, budesonide, mometasone) suppress local nasal inflammation and provide excellent symptom control — typically 50-60% reduction in nasal symptoms when used consistently. However, they require daily use indefinitely, provide no benefit after stopping, and do not modify the underlying immune response. Allergy shots produce immune system reprogramming — a 30-40% reduction in symptoms that persists for years after completing the course, reducing future medication dependence. For patients with moderate-to-severe seasonal pollen allergies inadequately controlled on nasal steroids plus antihistamines, immunotherapy offers the added benefit of disease modification. Many patients use nasal steroids for immediate symptom control during the first 6-12 months of immunotherapy while waiting for shots to take effect, then taper off medication as immunotherapy benefit becomes established.